BLAINE LABORATORIES, INC. – Trademark Portfolio
Entity Type: 03
BLAINE LABORATORIES, INC. holds 39 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 27 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 3 Nice Classification classes. Currently, 19 trademarks are registered. Notable registered marks include SIL K, VYOVA, VITÉ20, CICASIL, and HEMO XR. The owner is based in SANTA FE SPRINGS, CA.
11037 LOCKPORT PL
SANTA FE SPRINGS, CA 90670
Showing of trademarks Trademarks
Trademark Classifications
BLAINE LABORATORIES, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does BLAINE LABORATORIES, INC. have?
BLAINE LABORATORIES, INC. has 39 U.S. trademarks filed with the USPTO. Of these, 19 registered, 15 abandoned, 5 cancelled.
What trademark classes does BLAINE LABORATORIES, INC. file in?
BLAINE LABORATORIES, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are BLAINE LABORATORIES, INC.'s most well-known trademarks?
BLAINE LABORATORIES, INC.'s registered trademark portfolio includes well-known marks such as SIL K, VYOVA, VITÉ20, CICASIL, and HEMO XR. These are among 19 currently registered trademarks in the portfolio.
What is BLAINE LABORATORIES, INC.'s trademark registration success rate?
BLAINE LABORATORIES, INC. has a 49% trademark registration rate, with 19 out of 39 resolved applications resulting in successful registration. Currently, 0 applications are pending review.